PhEED, a new RCT for post ischemic or hemorrhagic stoke patients with dysphagia has started enrollment in the US and Europe

Pharyngeal Electrical Stimulation Evaluation for Dysphagia after Stroke (PhEED) is a prospective multi-centre randomised controlled single-blinded trial with Non-Significant Risk status granted by FDA. If you are a healthcare professional working in an acute rehab center and are interested in being part of PhEED in US, please contact Nadine Juran at For more information click here.


PhEED is a research study to test the safety and performance of the Phagenyx System for the treatment of swallowing problems of US patients after stroke. The Phagenyx System is not yet approved for commercial use by the U.S. Food and Drug Administration (FDA) and it is therefore considered an investigational device used only in research.

The Phagenyx System was approved for sale in Europe in 2012 and is currently being used to treat patients with neurogenic dysphagia including post-stroke dysphagia.